Karina Gomez

Karina Gomez

Auto-generated profile, based on publicly available information

Karina Gomez

Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado. 1

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
RIRitsuko Iwanaga
Ritsuko Iwanaga
TYTomomi M. Yamamoto
Tomomi M. Yamamoto
KGKarina Gomez
Karina Gomez
LNLily L. Nguyen
Lily L. Nguyen
EWElizabeth R. Woodruff
Elizabeth R. Woodruff
LBLindsay Wheeler Brubaker
Lindsay Wheeler Brubaker
Chromobox 2 (CBX2), an epigenetic reader and component of polycomb repressor complex 1, is highly expressed in >75% of high-grade serous carcinoma. Increased CBX2 expression is associated with poorer survival, whereas CBX2 knockdown leads to improved chemotherapy sensitivity. In a high-grade serous carcinoma immune-competent murine model, knockdown of CBX2 decreased tumor progression. We sought to explore the impact of modulation of CBX2 on the tumor immune microenvironment (TIME), understanding that the TIME plays a critical role in disease progression and development of therapy resistance. Exploration of existing datasets demonstrated that elevated CBX2 expression significantly correlated with specific immune cell types in the TIME. RNA sequencing and pathway analysis of differentially expressed genes demonstrated immune signature enrichment. Confocal microscopy and co-culture experiments found that modulation of CBX2 leads to increased recruitment and infiltration of macrophages. Flow cytometry of macrophages cultured with CBX2-overexpressing cells showed increased M2-like macrophages and decreased phagocytosis activity. Cbx2 knockdown in the Trp53-null, Brca2-null ID8 syngeneic murine model (ID8 Trp53−/−Brca2−/−) led to decreased tumor progression compared with the control. NanoString immuno-oncology panel analysis suggested that knockdown in Cbx2 shifts immune cell composition, with an increase in macrophages. Multispectral immunohistochemistry (mIHC) further confirmed an increase in macrophage infiltration. Increased CBX2 expression leads to recruitment and polarization of protumor macrophages, and targeting CBX2 may serve to modulate the TIME to enhance the efficacy of immune therapies. Significance: CBX2 expression correlates with the TIME. CBX2 modulation shifts the macrophage population, potentially leading to an immunosuppressive microenvironment, highlighting CBX2 as a target to improve efficacy of immunotherapy.

28 March 2025
Verified
Other
Open access
RIRitsuko Iwanaga
Ritsuko Iwanaga
TYTomomi M. Yamamoto
Tomomi M. Yamamoto
KGKarina Gomez
Karina Gomez
LNLily L. Nguyen
Lily L. Nguyen
EWElizabeth R. Woodruff
Elizabeth R. Woodruff
LBLindsay Wheeler Brubaker
Lindsay Wheeler Brubaker
Modulation of CBX2 enhances monocyte infiltration


28 March 2025
Verified
Other
Open access
RIRitsuko Iwanaga
Ritsuko Iwanaga
TYTomomi M. Yamamoto
Tomomi M. Yamamoto
KGKarina Gomez
Karina Gomez
LNLily L. Nguyen
Lily L. Nguyen
EWElizabeth R. Woodruff
Elizabeth R. Woodruff
LBLindsay Wheeler Brubaker
Lindsay Wheeler Brubaker
CBX2 binds to promoter regions of cytokine genes and CBX2 is significantly associated with immune signatures.

28 March 2025
Verified
Other
Open access
RIRitsuko Iwanaga
Ritsuko Iwanaga
TYTomomi M. Yamamoto
Tomomi M. Yamamoto
KGKarina Gomez
Karina Gomez
LNLily L. Nguyen
Lily L. Nguyen
EWElizabeth R. Woodruff
Elizabeth R. Woodruff
LBLindsay Wheeler Brubaker
Lindsay Wheeler Brubaker
Overview of supplementary data

28 March 2025
Verified
Other
Open access
RIRitsuko Iwanaga
Ritsuko Iwanaga
TYTomomi M. Yamamoto
Tomomi M. Yamamoto
KGKarina Gomez
Karina Gomez
LNLily L. Nguyen
Lily L. Nguyen
EWElizabeth R. Woodruff
Elizabeth R. Woodruff
LBLindsay Wheeler Brubaker
Lindsay Wheeler Brubaker
M1/M2 macrophages convey differential survival outcomes. M1/M2 gating strategy. CD68 gating of monocytes in culture system.